Research director Brianna Cartwright shares Truveta's look at early oral semaglutide use for obesity at AMCP Nexus in San Diego on October 28.
Recap by typeshit. Post by Truveta on X.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
The group says peptides show promise but lack clinical validation, and lays out points patients should weigh first.
Imperial College London researchers used it to compare three GLP-1 agonist candidates, getting matching results in about one hour instead of four.
Loading…